Journal of Clinical Medicine (Nov 2022)

Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination

  • Ana I. Molina-Ramos,
  • Elisabeth Gómez-Moyano,
  • Jorge Rodríguez-Capitán,
  • María Angullo-Gómez,
  • Patricia Gallardo-Jiménez,
  • Iván Pérez de Pedro,
  • Lucía Valiente de Santis,
  • Beatriz Pérez-Villardón,
  • Isabel Piñero-Uribe,
  • Javier Mora-Robles,
  • Víctor Manuel Becerra-Muñoz,
  • Manuel Jiménez-Navarro

DOI
https://doi.org/10.3390/jcm11236999
Journal volume & issue
Vol. 11, no. 23
p. 6999

Abstract

Read online

The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.

Keywords